Arcturus Therapeutics Statistics
Share Statistics
Arcturus Therapeutics has 27.12M
shares outstanding. The number of shares has increased by 0.7%
in one year.
| Shares Outstanding | 27.12M |
| Shares Change (YoY) | 0.7% |
| Shares Change (QoQ) | 0.12% |
| Owned by Institutions (%) | 98.46% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 245 |
| FTD / Avg. Volume | 0.06% |
Short Selling Information
The latest short interest is 5.14M, so 18.94% of the outstanding
shares have been sold short.
| Short Interest | 5.14M |
| Short % of Shares Out | 18.94% |
| Short % of Float | 29.67% |
| Short Ratio (days to cover) | 14.18 |
Valuation Ratios
The PE ratio is -5.66 and the forward
PE ratio is -3.02.
Arcturus Therapeutics's PEG ratio is
-0.03.
| PE Ratio | -5.66 |
| Forward PE | -3.02 |
| PS Ratio | 3.31 |
| Forward PS | 0.4 |
| PB Ratio | 1.9 |
| P/FCF Ratio | -7.59 |
| PEG Ratio | -0.03 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Arcturus Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.67,
with a Debt / Equity ratio of 0.12.
| Current Ratio | 4.67 |
| Quick Ratio | 4.67 |
| Debt / Equity | 0.12 |
| Debt / EBITDA | -0.37 |
| Debt / FCF | -0.47 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $795,339.08 |
| Profits Per Employee | $-465,178.16 |
| Employee Count | 174 |
| Asset Turnover | 0.4 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -4K |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -60.85% in the
last 52 weeks. The beta is 2.37, so Arcturus Therapeutics's
price volatility has been higher than the market average.
| Beta | 2.37 |
| 52-Week Price Change | -60.85% |
| 50-Day Moving Average | 11.79 |
| 200-Day Moving Average | 17.03 |
| Relative Strength Index (RSI) | 49.55 |
| Average Volume (20 Days) | 434,270 |
Income Statement
In the last 12 months, Arcturus Therapeutics had revenue of 138.39M
and earned -80.94M
in profits. Earnings per share was -3.
| Revenue | 138.39M |
| Gross Profit | 134.84M |
| Operating Income | -95.67M |
| Net Income | -80.94M |
| EBITDA | -77.4M |
| EBIT | -80.94M |
| Earnings Per Share (EPS) | -3 |
Full Income StatementBalance Sheet
The company has 237.03M in cash and 28.55M in
debt, giving a net cash position of 208.48M.
| Cash & Cash Equivalents | 237.03M |
| Total Debt | 28.55M |
| Net Cash | 208.48M |
| Retained Earnings | -448.81M |
| Total Assets | 331.79M |
| Working Capital | 229.38M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -59.75M
and capital expenditures -648K, giving a free cash flow of -60.4M.
| Operating Cash Flow | -59.75M |
| Capital Expenditures | -648K |
| Free Cash Flow | -60.4M |
| FCF Per Share | -2.24 |
Full Cash Flow StatementMargins
Gross margin is 97.44%, with operating and profit margins of -69.13% and -58.49%.
| Gross Margin | 97.44% |
| Operating Margin | -69.13% |
| Pretax Margin | -58.49% |
| Profit Margin | -58.49% |
| EBITDA Margin | -55.93% |
| EBIT Margin | -69.13% |
| FCF Margin | -43.64% |
